Clinical trial

Intravenous Tranexamic Acid

Opening soon · Not applicable · 1 countries · Registry ID NCT07192640

Opening soonNot applicableInterventional

What this study is about

Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 60 Years

SexAll

Healthy volunteersNot accepted

ConditionObese Patients, Obese Patients With Bariatric Surgery, Bleeding

Full registry criteria

Inclusion Criteria: * High-risk patients, with obesity, BMI more than 45, * Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders. Exclusion Criteria: * patients with active thromboembolic disorders. * Patients with preexisting renal dysfunction,

Treatments and study arms

After induction of anaesthesia tranexamic acid will be administered at the start of surgery to reduce intraoperative bleeding. loading dose of 10 mg/kg for high BMI patients who are undergoing bariatr

Drug

This intervention will be applied for High-risk patients, with obesity, BMI more than 45, Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.

Primary outcomes

Intraoperative blood Loss"Perioperative"

Intraoperative and postoperative Blood Loss will be calculated in the suction and wet gauzes by blood and the need for blood transfusion will be recorded

Study locations

1 locations were listed when this page was built. The first 40 are shown.

King Salman Specialist Hospital, Hail, KSA🌐 Ha'il, Saudi Arabia

Open map

Saad Abdullah Alrasheedi, Chairman, Institutional BoardContact

Email · Call 966162362222

Study contactContact